Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial

Minami, Junichi; Kondo, Shizuki; Yanagisawa, Naotake; Odamaki, Toshitaka; Xiao, Jin‐zhong; Abe, Fumiaki; Nakajima, Shigeru; Hamamoto, Yukie; Saitoh, Sanae; Shimoda, Taeko

doi:10.1017/jns.2015.5

Cited by 89 publications

(87 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, there are few clinical studies evaluating the efficacy of probiotic bifidobacteria on visceral fat in humans. Minami et al reported that consumption of B. breve B-3 reduced fat mass measured by a bioelectrical impedance method in adults but did not reveal a change in visceral adipose tissue [33]. In the present study, we clearly demonstrated the utility of probiotic bifidobacteria to reduce visceral fat in humans, as in previous animal studies [30,31,32].…”

Section: Discussionsupporting

confidence: 86%

Effect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial

Takahashi

Anzawa

Kazuyo

et al. 2016

Bioscience of Microbiota, Food and Health

View full text Add to dashboard Cite

Bifidobacterium animalis ssp. lactis GCL2505 (B. lactis GCL2505) is able to survive passage through the intestine and then proliferate, leading to an increase in the amount of gut bifidobacteria. In the present study, we evaluated the impact of B. lactis GCL2505 on abdominal visceral fat storage in overweight and mildly obese Japanese adults. This clinical study was a double-blind, randomized, placebo-controlled, parallel-group comparative trial performed for 12 weeks. Healthy Japanese subjects (N=137) with body mass indices ranging from 23 to 30 kg/m2 consumed either fermented milk containing B. lactis GCL2505 or a placebo every day, and then visceral and subcutaneous abdominal fat areas were measured by computed tomography as the primary endpoints. The number of fecal bifidobacteria was also measured. Visceral fat area, but not subcutaneous fat area, was significantly reduced from baseline at 8 and 12 weeks in the GCL2505 group, compared with the placebo group. The total number of fecal bifidobacteria was significantly increased in the GCL2505 group. These results indicate that B. lactis GCL2505 reduces abdominal visceral fat, a key factor associated with metabolic disorders. This finding suggests that this probiotic strain can potentially serve as a specific functional food to achieve visceral fat reduction in overweight or mildly obese individuals.

show abstract

Section: Discussionsupporting

confidence: 86%

Effect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial

Takahashi

Anzawa

Kazuyo

et al. 2016

Bioscience of Microbiota, Food and Health

View full text Add to dashboard Cite

show abstract

“…Four clinical studies involving healthy, overweight and/or obese participants have investigated the effects of micro-organisms on weight management or body fat mass (Kadooka et al, 2010, Kadooka et al, 2013, Minami et al, 2015, Sanchez et al, 2014). The effect size seen in the current study (6.7% difference in trunk fat between LU + B420 and Placebo) is quite comparable to that seen in 12-week interventions with Lactobacillus gasseri SBT2055 where abdominal fat was reduced by approximately 4.5% compared to placebo (Kadooka et al, 2010, Kadooka et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

“…It is difficult to compare the employed statistical methodology, however, because it remains unclear which participants were included in the analyses. In comparison, intake of Bifidobacterium breve B-3 reduced body fat mass by 0.6 kg compared to placebo within 12 weeks (Minami et al, 2015). It should also be noted that the study participants in these three studies were Japanese whereas the present study was conducted on a Western population.…”

Section: Discussionmentioning

confidence: 99%

Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial

et al. 2016

View full text Add to dashboard Cite

BackgroundThe gut microbiota is interlinked with obesity, but direct evidence of effects of its modulation on body fat mass is still scarce. We investigated the possible effects of Bifidobacterium animalisssp. lactis 420 (B420) and the dietary fiber Litesse® Ultra polydextrose (LU) on body fat mass and other obesity-related parameters.Methods225 healthy volunteers (healthy, BMI 28–34.9) were randomized into four groups (1:1:1:1), using a computer-generated sequence, for 6 months of double-blind, parallel treatment: 1) Placebo, microcrystalline cellulose, 12 g/d; 2) LU, 12 g/d; 3) B420, 1010 CFU/d in microcrystalline cellulose, 12 g/d; 4) LU + B420, 12 g + 1010 CFU/d. Body composition was monitored with dual-energy X-ray absorptiometry, and the primary outcome was relative change in body fat mass, comparing treatment groups to Placebo. Other outcomes included anthropometric measurements, food intake and blood and fecal biomarkers. The study was registered in Clinicaltrials.gov (NCT01978691).FindingsThere were marked differences in the results of the Intention-To-Treat (ITT; n = 209) and Per Protocol (PP; n = 134) study populations. The PP analysis included only those participants who completed the intervention with > 80% product compliance and no antibiotic use. In addition, three participants were excluded from DXA analyses for PP due to a long delay between the end of intervention and the last DXA measurement. There were no significant differences between groups in body fat mass in the ITT population. However, LU + B420 and B420 seemed to improve weight management in the PP population. For relative change in body fat mass, LU + B420 showed a − 4.5% (− 1.4 kg, P = 0.02, N = 37) difference to the Placebo group, whereas LU (+ 0.3%, P = 1.00, N = 35) and B420 (− 3.0%, P = 0.28, N = 24) alone had no effect (overall ANOVA P = 0.095, Placebo N = 35). A post-hoc factorial analysis was significant for B420 (− 4.0%, P = 0.002 vs. Placebo). Changes in fat mass were most pronounced in the abdominal region, and were reflected by similar changes in waist circumference. B420 and LU + B420 also significantly reduced energy intake compared to Placebo. Changes in blood zonulin levels and hsCRP were associated with corresponding changes in trunk fat mass in the LU + B420 group and in the overall population. There were no differences between groups in the incidence of adverse events.DiscussionThis clinical trial demonstrates that a probiotic product with or without dietary fiber controls body fat mass. B420 and LU + B420 also reduced waist circumference and food intake, whereas LU alone had no effect on the measured outcomes.

show abstract

“…lactis CNCM I-2494Vegetable and dairy productsEach strain selectively altered a specific subset of key bacteria species that were significantly associated with MS.[15]Partially reversed HFD-induced structural changes in the gut microbiota Significant reduction in TNF-α expression in HFD-fed mice. Bifidobacterium breve B-3Healthy infantSignificantly lowering fat mass in human subjects. Improvements in some blood parameters related to liver function and inflammation.[30] Lactobacillus gasseri SBT2055Fecal specimen of a healthy adultLG2055 dose-dependently suppressed lipase activity in the fat emulsion assay. LG2055 dose-dependently increased fat emulsion droplet size.[31] Lactobacillus rhamnosus GG Lactobacillus paracasei TMC0409 Significant reduction in weight, fat accumulation and adipocyte fatty acid synthase (FAS) activity.…”

Section: Probiotic Lab and Obesity Treatmentmentioning

confidence: 99%

Some current applications, limitations and future perspectives of lactic acid bacteria as probiotics

Evivie

Gui-cheng

Igene

et al. 2017

Food & Nutrition Research

141

View full text Add to dashboard Cite

Several mechanism and non-mechanism-based studies supporting the claim that lactic acid bacteria (LAB) strains confer health benefits and play immune-modulatory roles were examined in this review. Probiotic applications of LAB on global burdens such as obesity and type-2 diabetes were discussed as well as the use of yoghurt and ice cream as important vehicles to convey several beneficial LAB strains. Probiotic and symbiotic dairy products may be used in the nearest future to treat a variety of health disorders. Current studies suggest that lactic acid bacteria possess anti-obesity and anti-diabetic propensities on their hosts and thus can play a crucial role in human health care. Research in the rheological and physicochemical properties of ice cream as well as its applications are also on the increase. These applications face certain hurdles including technological (for less developed countries), consumer acceptability of new functional foods may be influenced by culture, ethics or religion. There is need for more studies on the genetic basis for probiotic properties which will give further understanding regarding novel manipulation skills and applicability in nutrition and health sectors. More studies confirming the direct effects of probiotic LABs in lowering the spread of food-borne and other pathogens are also anticipated.

show abstract

Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial

Cited by 89 publications

References 48 publications

Effect of <i>Bifidobacterium animalis</i> ssp. <i>lactis</i> GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial

Effect of <i>Bifidobacterium animalis</i> ssp. <i>lactis</i> GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial

Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial

Some current applications, limitations and future perspectives of lactic acid bacteria as probiotics

Contact Info

Product

Resources

About